Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × OTHER × MCRC × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1594 Carcinoma, Non-Small-Cell Lung 1119 Prostatic Neoplasms 844 Colorectal Neoplasms 702 Multiple Myeloma 623 Leukemia, Myeloid, Acute 600 Neoplasms 567 Lung Neoplasms 566 Neoplasm Metastasis 538 Lymphoma 482 Pancreatic Neoplasms 480 Carcinoma, Hepatocellular 469 Stomach Neoplasms 441 Leukemia 436 Recurrence 422 Melanoma 382 Leukemia, Lymphocytic, Chronic, B-Cell 374 Ovarian Neoplasms 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma 367 Lymphoma, Non-Hodgkin 360 Myelodysplastic Syndromes 352 Squamous Cell Carcinoma of Head and Neck 349 Lymphoma, Large B-Cell, Diffuse 349 Head and Neck Neoplasms 342 Brain Neoplasms 338 Rectal Neoplasms 330 Glioblastoma 329 Carcinoma, Renal Cell 287 Lymphoma, Follicular 280 Hodgkin Disease 280

Interventions

tislelizumab 1 regorafenib 1 Trace amine-associated receptor 1 1 Thymalfasin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06829355 2025-02-17

THYMI

Beijing Friendship Hospital

Phase 2 Recruiting

MCRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡